Top Clinical Trials companies in Australia by EBT Margin

This ranking features the top 15 Clinical Trials companies in Australia ranked by EBT Margin, averaging a EBT Margin of -22,863.86%, for February 07, 2025.
#
Name
EBT Margin
Reported Date
Stock Price
Change
Price (30 days) Country
1
57.47%
June 30, 2024 USD 7.25 -0.16%

Australia

2
22.97%
June 30, 2024 USD 171.50 0.95%

Australia

3
16.06%
June 30, 2024 USD 0.74 0.02%

Australia

4
5.27%
June 30, 2024 USD 2.33 0.29%

Australia

5
1.66%
June 30, 2024 USD 1.23 0.02%

Australia

6
0.62%
Dec. 31, 2023 USD 18.31 -0.05%

Australia

7
-4.18%
June 30, 2024 USD 0.74 0.02%

Australia

8
-141.49%
June 30, 2024 USD 2.04 -5.56%

Australia

9
-365.26%
June 30, 2024 USD 2.34 -4.83%

Australia

10
-474.65%
June 30, 2024 USD 4.80 5.03%

Australia

11
-1,111.87%
June 30, 2024 USD 2.09 0.97%

Australia

12
-1,493.51%
June 30, 2024 USD 1.84 -3.30%

Australia

13
-1,680.35%
Dec. 31, 2023 USD 6.22 1.04%

Australia

14
-153,575.00%
June 30, 2024 USD 1.67 2.45%

Australia

15
-184,215.67%
June 30, 2024 NA

Australia

Frequently Asked Questions
  • Which Clinical Trials company in Australia has the highest EBT Margin ?

    The Clinical Trials company in Australia with the highest EBT Margin is Clinuvel Pharmaceuticals Limited (ASX: CUV.AX) at 57.47%.

  • Which Clinical Trials company in Australia has the lowest EBT Margin ?

    The Clinical Trials company in Australia with the lowest EBT Margin is Opthea Limited (ASX: OPT.AX) at -184,215.67%.

SV Wall Street